T细胞淋巴瘤-话题@MedSci

#T细胞淋巴瘤#

96篇内容 | 3864人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1372644, encodeId=b2eb13e26441d, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=西达本胺治疗外周T细胞淋巴瘤中国专家共识（2018年版）, objectType=article, longId=148167, objectId=f37114816eaa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f37114816eaa, replyNumber=0, likeNumber=42, createdTime=2018-09-05, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f37114816eaa, moduleTitle=西达本胺治疗外周T细胞淋巴瘤中国专家共识（2018年版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f37114816eaa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372643, encodeId=10ff13e264360, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=NCCN临床实践指南：T细胞淋巴瘤（2018.V5）, objectType=article, longId=146746, objectId=313c146e46f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=313c146e46f5, replyNumber=0, likeNumber=33, createdTime=2018-08-17, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=313c146e46f5, moduleTitle=NCCN临床实践指南：T细胞淋巴瘤（2018.V5）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=313c146e46f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372642, encodeId=477913e264210, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=柳叶刀公布了Kyowa Kirin公司CCR4单抗Poteligeo 治疗皮肤T细胞淋巴瘤的III期临床数据, objectType=article, longId=146735, objectId=31ee146e35d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31ee146e35d9, replyNumber=0, likeNumber=72, createdTime=2018-08-17, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31ee146e35d9, moduleTitle=柳叶刀公布了Kyowa Kirin公司CCR4单抗Poteligeo 治疗皮肤T细胞淋巴瘤的III期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31ee146e35d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372641, encodeId=07b013e264115, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Blood：抗CD37嵌合抗原受体T细胞可有效治疗B/T细胞淋巴瘤, objectType=article, longId=146567, objectId=eb5714656e5e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb5714656e5e, replyNumber=0, likeNumber=102, createdTime=2018-08-15, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb5714656e5e, moduleTitle=Blood：抗CD37嵌合抗原受体T细胞可有效治疗B/T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb5714656e5e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372640, encodeId=e72013e2640f7, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Blood：在自然杀伤T细胞淋巴瘤中，STAT3信号通路激活可上调PD-L1的表达！, objectType=article, longId=145638, objectId=7bf3145638e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bf3145638e4, replyNumber=0, likeNumber=130, createdTime=2018-08-03, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bf3145638e4, moduleTitle=Blood：在自然杀伤T细胞淋巴瘤中，STAT3信号通路激活可上调PD-L1的表达！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bf3145638e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372639, encodeId=295613e263939, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Blood：Brentuximab Vedotin+CHP一线治疗外周T细胞淋巴瘤5年结局喜人：客观反应率高达100%！, objectType=article, longId=138647, objectId=e39113864ec6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e39113864ec6, replyNumber=0, likeNumber=71, createdTime=2018-05-21, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e39113864ec6, moduleTitle=Blood：Brentuximab Vedotin+CHP一线治疗外周T细胞淋巴瘤5年结局喜人：客观反应率高达100%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e39113864ec6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372638, encodeId=efe313e2638b5, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Blood：RhoA G17V突变可促进形成具有滤泡辅助T细胞特性的T细胞淋巴瘤, objectType=article, longId=138446, objectId=305b13844696, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=305b13844696, replyNumber=0, likeNumber=84, createdTime=2018-05-19, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=305b13844696, moduleTitle=Blood：RhoA G17V突变可促进形成具有滤泡辅助T细胞特性的T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=305b13844696)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372637, encodeId=288913e2637b5, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=NCCN临床实践指南：T细胞淋巴瘤（2018.V4）, objectType=article, longId=138370, objectId=0c6a1383e00d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c6a1383e00d, replyNumber=0, likeNumber=40, createdTime=2018-05-18, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c6a1383e00d, moduleTitle=NCCN临床实践指南：T细胞淋巴瘤（2018.V4）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c6a1383e00d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372636, encodeId=4e2013e2636d3, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=伴面部肿胀结外鼻型NK/T细胞淋巴瘤死亡1例, objectType=article, longId=135294, objectId=273b1352945b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=273b1352945b, replyNumber=0, likeNumber=74, createdTime=2018-04-15, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=273b1352945b, moduleTitle=伴面部肿胀结外鼻型NK/T细胞淋巴瘤死亡1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=273b1352945b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372635, encodeId=cb0d13e26351e, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Blood：鼻型结外NK/T细胞淋巴瘤的治疗进展, objectType=article, longId=134102, objectId=500b13410298, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=500b13410298, replyNumber=0, likeNumber=67, createdTime=2018-04-04, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=500b13410298, moduleTitle=Blood：鼻型结外NK/T细胞淋巴瘤的治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=500b13410298)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372634, encodeId=57d213e26347d, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性, objectType=article, longId=131784, objectId=6781131e84a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6781131e84a3, replyNumber=0, likeNumber=60, createdTime=2018-03-09, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6781131e84a3, moduleTitle=Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6781131e84a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372633, encodeId=d9ef13e263321, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=NCCN临床实践指南：T细胞淋巴瘤（2018.V3）, objectType=article, longId=131494, objectId=c70113149432, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c70113149432, replyNumber=0, likeNumber=33, createdTime=2018-03-06, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c70113149432, moduleTitle=NCCN临床实践指南：T细胞淋巴瘤（2018.V3）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c70113149432)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372632, encodeId=51a913e263217, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Haematologica：剂量调整的EPOCH化疗能改善外周T细胞淋巴瘤患者结局？, objectType=article, longId=130749, objectId=b8ba130e490e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ba130e490e, replyNumber=0, likeNumber=58, createdTime=2018-02-28, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ba130e490e, moduleTitle=Haematologica：剂量调整的EPOCH化疗能改善外周T细胞淋巴瘤患者结局？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8ba130e490e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372631, encodeId=c34913e2631c9, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=ANN ONCOL：Ⅰ/Ⅱ期NK/T细胞淋巴瘤序贯化疗/放疗与同时放化疗效果相似, objectType=article, longId=128008, objectId=63581280084d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63581280084d, replyNumber=0, likeNumber=118, createdTime=2018-01-29, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63581280084d, moduleTitle=ANN ONCOL：Ⅰ/Ⅱ期NK/T细胞淋巴瘤序贯化疗/放疗与同时放化疗效果相似, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63581280084d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372630, encodeId=73b413e263065, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=NCCN临床实践指南：T细胞淋巴瘤（2018.V2）, objectType=article, longId=125479, objectId=39601254e95c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39601254e95c, replyNumber=0, likeNumber=40, createdTime=2018-01-05, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39601254e95c, moduleTitle=NCCN临床实践指南：T细胞淋巴瘤（2018.V2）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39601254e95c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372629, encodeId=e98b13e26298c, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=张会来教授：外周T细胞淋巴瘤和NK/T细胞淋巴瘤的研究进展, objectType=article, longId=124109, objectId=73a712410935, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73a712410935, replyNumber=0, likeNumber=70, createdTime=2017-12-22, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73a712410935, moduleTitle=张会来教授：外周T细胞淋巴瘤和NK/T细胞淋巴瘤的研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73a712410935)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372628, encodeId=87f413e2628db, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=Blood：PI3K-δ/γ抑制剂duvelisib用于T细胞淋巴瘤的活性。, objectType=article, longId=123385, objectId=165a123385bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=165a123385bf, replyNumber=0, likeNumber=59, createdTime=2017-12-15, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=165a123385bf, moduleTitle=Blood：PI3K-δ/γ抑制剂duvelisib用于T细胞淋巴瘤的活性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=165a123385bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372627, encodeId=602913e2627f7, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案, objectType=article, longId=123207, objectId=4dfc12320e42, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dfc12320e42, replyNumber=0, likeNumber=34, createdTime=2017-12-14, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dfc12320e42, moduleTitle=【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dfc12320e42)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372626, encodeId=876013e2626ee, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=范磊教授：结外NK/T细胞淋巴瘤基础与治疗新近进展概览, objectType=article, longId=123147, objectId=68f812314e6b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68f812314e6b, replyNumber=0, likeNumber=81, createdTime=2017-12-14, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68f812314e6b, moduleTitle=范磊教授：结外NK/T细胞淋巴瘤基础与治疗新近进展概览, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68f812314e6b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1372625, encodeId=b2f313e26254d, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, objectTitle=【ASH 2017】CR后一线造血干细胞移植巩固在外周T细胞淋巴瘤中的价值：一项前瞻性多中心临床研究, objectType=article, longId=120900, objectId=190612090080, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=190612090080, replyNumber=0, likeNumber=108, createdTime=2017-11-22, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=190612090080, moduleTitle=【ASH 2017】CR后一线造血干细胞移植巩固在外周T细胞淋巴瘤中的价值：一项前瞻性多中心临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=190612090080)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

T细胞淋巴瘤

2020-05-29

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

西达本胺治疗外周T细胞淋巴瘤中国专家共识（2018年版）

2018-09-05

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

NCCN临床实践指南：T细胞淋巴瘤（2018.V5）

2018-08-17

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

柳叶刀公布了Kyowa Kirin公司CCR4单抗Poteligeo 治疗皮肤T细胞淋巴瘤的III期临床数据

2018-08-17

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Blood：抗CD37嵌合抗原受体T细胞可有效治疗B/T细胞淋巴瘤

2018-08-15

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Blood：在自然杀伤T细胞淋巴瘤中，STAT3信号通路激活可上调PD-L1的表达！

2018-08-03

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Blood：Brentuximab Vedotin+CHP一线治疗外周T细胞淋巴瘤5年结局喜人：客观反应率高达100%！

2018-05-21

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Blood：RhoA G17V突变可促进形成具有滤泡辅助T细胞特性的T细胞淋巴瘤

2018-05-19

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

NCCN临床实践指南：T细胞淋巴瘤（2018.V4）

2018-05-18

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

伴面部肿胀结外鼻型NK/T细胞淋巴瘤死亡1例

2018-04-15

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Blood：鼻型结外NK/T细胞淋巴瘤的治疗进展

2018-04-04

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Blood：brentuximab vedotin联合环磷酰胺、阿霉素和强的松作为一线治疗方案用于外周T细胞淋巴瘤患者的疗效和安全性

2018-03-09

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

NCCN临床实践指南：T细胞淋巴瘤（2018.V3）

2018-03-06

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Haematologica：剂量调整的EPOCH化疗能改善外周T细胞淋巴瘤患者结局？

2018-02-28

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

ANN ONCOL：Ⅰ/Ⅱ期NK/T细胞淋巴瘤序贯化疗/放疗与同时放化疗效果相似

2018-01-29

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

NCCN临床实践指南：T细胞淋巴瘤（2018.V2）

2018-01-05

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

张会来教授：外周T细胞淋巴瘤和NK/T细胞淋巴瘤的研究进展

2017-12-22

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

Blood：PI3K-δ/γ抑制剂duvelisib用于T细胞淋巴瘤的活性。

2017-12-15

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案

2017-12-14

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

范磊教授：结外NK/T细胞淋巴瘤基础与治疗新近进展概览

2017-12-14

aliceclz (审核中...)

前往app查看评论内容

#T细胞淋巴瘤#

【ASH 2017】CR后一线造血干细胞移植巩固在外周T细胞淋巴瘤中的价值：一项前瞻性多中心临床研究

2017-11-22

科室
- - 订阅+
  - 更多科室
工具
服务